The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.

A tidy reference review of incretin pharmacology from a veteran of the drug-mechanism literature. The most useful sections for our readers explain the molecular engineering behind long-acting peptides — fatty acid acylation piggybacking on albumin — and lay out the current approval map, with retatrutide still in trials. Nothing new here, but a well-organized primer on how this drug class actually works.